These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11785702)

  • 21. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal iontophoretic drug delivery: advances and challenges.
    Ita K
    J Drug Target; 2016; 24(5):386-91. PubMed ID: 26406291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene and antisense delivery in alcoholism research.
    Israel Y; Crews FT; Thurman RG; Tu GC; Garver E; Ponnappa B; Karahanian E; Rubin R; Hoplight B; Sethna M; Hanes R; Wilkie MB; Wheeler MD
    Alcohol Clin Exp Res; 2002 Apr; 26(4):582-5. PubMed ID: 11981136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microneedle-Mediated Transdermal Delivery of Bevacizumab.
    Courtenay AJ; McCrudden MTC; McAvoy KJ; McCarthy HO; Donnelly RF
    Mol Pharm; 2018 Aug; 15(8):3545-3556. PubMed ID: 29996645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin.
    Pannier AK; Arora V; Iversen PL; Brand RM
    Int J Pharm; 2004 May; 275(1-2):217-26. PubMed ID: 15081152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-Phase Iontophoresis for the Delivery of Antisense Oligonucleotides.
    Gibson DJ; Tuli SS; Schultz GS
    Nucleic Acid Ther; 2017 Aug; 27(4):238-250. PubMed ID: 28375679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats.
    Ponnappa BC; Dey I; Tu GC; Zhou F; Aini M; Cao QN; Israel Y
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1129-36. PubMed ID: 11356938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraocular delivery of oligonucleotides.
    Gomes Dos Santos AL; Bochot A; Fattal E
    Curr Pharm Biotechnol; 2005 Feb; 6(1):7-15. PubMed ID: 15727552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Transdermal therapeutic systems].
    Sugibayashi K; Morimoto Y
    Nihon Rinsho; 1998 Mar; 56(3):619-27. PubMed ID: 9549346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of peptides for tissue-specific delivery.
    Heemskerk H
    Methods Mol Biol; 2012; 867():379-92. PubMed ID: 22454074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers.
    Jääskeläinen I; Lappalainen K; Honkakoski P; Urtti A
    Methods Enzymol; 2004; 387():210-30. PubMed ID: 15172166
    [No Abstract]   [Full Text] [Related]  

  • 32. Dissolving microneedles for transdermal drug delivery: Advances and challenges.
    Ita K
    Biomed Pharmacother; 2017 Sep; 93():1116-1127. PubMed ID: 28738520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly (vinyl alcohol) microneedles: Fabrication, characterization, and application for transdermal drug delivery of doxorubicin.
    Nguyen HX; Bozorg BD; Kim Y; Wieber A; Birk G; Lubda D; Banga AK
    Eur J Pharm Biopharm; 2018 Aug; 129():88-103. PubMed ID: 29800617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo evaluation of a microneedle array device for transdermal application.
    Indermun S; Choonara YE; Kumar P; du Toit LC; Modi G; van Vuuren S; Luttge R; Pillay V
    Int J Pharm; 2015 Dec; 496(2):351-9. PubMed ID: 26453791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iontophoretic drug delivery system: a review.
    Semalty A; Semalty M; Singh R; Saraf SK; Saraf S
    Technol Health Care; 2007; 15(4):237-45. PubMed ID: 17673833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions.
    Astriab-Fisher A; Sergueev D; Fisher M; Shaw BR; Juliano RL
    Pharm Res; 2002 Jun; 19(6):744-54. PubMed ID: 12134943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled transdermal delivery of leuprorelin by pulsed iontophoresis and ion-exchange fiber.
    Malinovskaja K; Laaksonen T; Hirvonen J
    Eur J Pharm Biopharm; 2014 Nov; 88(3):594-601. PubMed ID: 25173088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides.
    González Ferreiro M; Tillman LG; Hardee G; Bodmeier R
    Pharm Res; 2002 Jun; 19(6):755-64. PubMed ID: 12134944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microneedles: A smart approach and increasing potential for transdermal drug delivery system.
    Waghule T; Singhvi G; Dubey SK; Pandey MM; Gupta G; Singh M; Dua K
    Biomed Pharmacother; 2019 Jan; 109():1249-1258. PubMed ID: 30551375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microneedles for transdermal drug delivery.
    Prausnitz MR
    Adv Drug Deliv Rev; 2004 Mar; 56(5):581-7. PubMed ID: 15019747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.